Switch theme
Sign up to access all valuation multiples
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
2020
130
LTM Revenue n/a
LTM EBITDA -$301M
-$280M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Acelyrin has a last 12-month revenue of n/a and a last 12-month EBITDA of -$301M.
In the most recent fiscal year, Acelyrin achieved revenue of n/a and an EBITDA of -$422M.
Acelyrin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Acelyrin valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$422M | -$331M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$41.8M | -$250M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Acelyrin's stock price is $3.
Acelyrin has current market cap of $276M, and EV of -$280M.
See Acelyrin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$280M | $276M | XXX | XXX | XXX | XXX | $-2.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Acelyrin has market cap of $276M and EV of -$280M.
Acelyrin's trades at n/a LTM EV/Revenue multiple, and 0.9x LTM EBITDA.
Analysts estimate Acelyrin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Acelyrin and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$280M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.8x | XXX | XXX | XXX |
| P/E | -1.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAcelyrin's NTM/LTM revenue growth is n/a
Acelyrin's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.2M for the same period.
Over next 12 months, Acelyrin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Acelyrin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Acelyrin and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -22% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acelyrin acquired XXX companies to date.
Last acquisition by Acelyrin was XXXXXXXX, XXXXX XXXXX XXXXXX . Acelyrin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Acelyrin founded? | Acelyrin was founded in 2020. |
| Where is Acelyrin headquartered? | Acelyrin is headquartered in United States of America. |
| How many employees does Acelyrin have? | As of today, Acelyrin has 130 employees. |
| Who is the CEO of Acelyrin? | Acelyrin's CEO is Ms. Mina Kim. |
| Is Acelyrin publicy listed? | Yes, Acelyrin is a public company listed on NAS. |
| What is the stock symbol of Acelyrin? | Acelyrin trades under SLRN ticker. |
| When did Acelyrin go public? | Acelyrin went public in 2023. |
| Who are competitors of Acelyrin? | Similar companies to Acelyrin include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Acelyrin? | Acelyrin's current market cap is $276M |
| What is the current EBITDA of Acelyrin? | Acelyrin's last 12-month EBITDA is -$301M. |
| What is the current EV/EBITDA multiple of Acelyrin? | Current EBITDA multiple of Acelyrin is 0.9x. |
| Is Acelyrin profitable? | Yes, Acelyrin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
